Hellenic Postprandial Lipemia Study (HPLS): A Prospective Cohort Trial on the Effect of Statins on Postprandial Hypertriglyceridemia

View at publisher
Authors: Genovefa D. Kolovou, Theodoros Katsikas, Petros G. Kalogeropoulos, Dimitris Panaretos, Vasiliki Giannakopoulou, Vana Kolovou, Stella A. Iraklianou, Sotiria J. Limberi, Vasileios Giannaris, Anna Kounali, Niki Katsiki, Despina N Perrea
+13 more Katerina Anagnostopoulou, Georgios S. Goumas, Evangelia Siami, Peggy Kostakou, Dimitri P. Mikhailidis, Gerald Francis Watts, Pablo Pérez‐Martínez, José López‐Miranda, Samia Mora, Børge Grønne Nordestgaard, Dennis V. Cokkinos, Nikolaos Tentolouris, Helen I. Bilianou
Cited by: 0

Abstract

INTRODUCTION/OBJECTIVE: Both fasting and postprandial hypertriglyceridemia are associated with atherosclerotic cardiovascular disease (ASCVD). The Hellenic Postprandial Lipemia Study (HPLS, NCT02163044) is the largest prospective cohort trial assessing the effects of statin therapy on postprandial lipemia. METHODS: Individuals at high or very high risk for ASCVD were evaluated, and their characteristics were recorded at baseline (Visit 1). At Visit 2 (2-4 weeks after Visit 1) and Visit 3 (3-4 months after Visit 2), serum triglyceride (TG) levels were measured after a 12-hour fast (fTG) as well as 4 hours after the ingestion of a commercially available oral fat tolerance test meal (pTG). After Visit 2, all individuals were treated with a statin. RESULTS AND DISCUSSION: Among 900 participants, 699 completed all 3 visits, and of these, 209 (29.9%) had an abnormal pTG response. The mean (standard deviation, SD) total- and low-density lipoprotein cholesterol concentrations were 225 (50) and 148 (46) mg/dL at Visit 1, 231 (42) and 156 (40) mg/dL at Visit 2, and 171 (28) and 101 (27) mg/dL at Visit 3. At Visit 2, the mean fTG level was 127 (45) mg/dL and pTG was 188 (73) mg/dL with a mean difference of 58 mg/dL (P

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Lipid metabolism and disorders Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
Current Vascular Pharmacology
Volume
24
Publication date
21 January 2026
Language
EN